CG Oncology executives will present at the J.P. Morgan Healthcare Conference on January 15, 2026, discussing bladder cancer therapies.
Quiver AI Summary
CG Oncology, Inc., a biopharmaceutical company focused on developing treatments for bladder cancer, announced that its leadership, Chairman and CEO Arthur Kuan and President and COO Ambaw Bellete, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will take place at 8:15 am PT / 11:15 am ET, in San Francisco, California. The live audio webcast of the presentation will be available on the company's website, with a replay offered for about 90 days afterward. CG Oncology aims to provide innovative immunotherapies to improve the lives of patients with bladder cancer.
Potential Positives
- CG Oncology is featured in the prestigious 44th Annual J.P. Morgan Healthcare Conference, highlighting the company's growing recognition in the biopharmaceutical industry.
- The presentation is an opportunity for CG Oncology's leadership to share insights about their innovative bladder-sparing therapeutic, potentially attracting investor interest and enhancing company visibility.
- The availability of a live audio webcast and subsequent replay indicates transparency and accessibility, fostering deeper engagement with stakeholders and the public.
Potential Negatives
- The press release lacks any new information regarding the company's progress or recent developments, which may lead to investor disappointment.
- There is no mention of recent financial performance or guidance, potentially raising concerns about the company's current financial health.
- The focus on an upcoming presentation without any accompanying news could suggest a lack of significant milestones since the last update, leading to doubts about the company's trajectory.
FAQ
What is CG Oncology's main focus?
CG Oncology specializes in developing and commercializing bladder-sparing therapeutics for bladder cancer patients.
When will CG Oncology present at the J.P. Morgan Healthcare Conference?
CG Oncology will present on January 15, 2026, at 8:15 am PT / 11:15 am ET.
Where can I watch the CG Oncology presentation live?
The live audio webcast will be available on the Investor Relations section of CG Oncology's website.
How long will the webcast replay be available?
The webcast replay will be archived for approximately 90 days after the live presentation.
Who are the presenters from CG Oncology at the conference?
Arthur Kuan, Chairman & CEO, and Ambaw Bellete, President & COO, will be presenting at the conference.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CGON Insider Trading Activity
$CGON insiders have traded $CGON stock on the open market 19 times in the past 6 months. Of those trades, 1 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $CGON stock by insiders over the last 6 months:
- BRIAN GUAN-CHYUN LIU purchased 1,515,151 shares for an estimated $49,999,983
- HONG FANG SONG has made 0 purchases and 4 sales selling 100,000 shares for an estimated $2,779,542.
- JAMES MULAY has made 0 purchases and 8 sales selling 68,359 shares for an estimated $2,496,247.
- LEONARD E POST has made 0 purchases and 6 sales selling 11,000 shares for an estimated $404,230.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CGON Hedge Fund Activity
We have seen 88 institutional investors add shares of $CGON stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 3,613,885 shares (+190.3%) to their portfolio in Q3 2025, for an estimated $145,567,287
- MORGAN STANLEY removed 1,225,734 shares (-65.6%) from their portfolio in Q3 2025, for an estimated $49,372,565
- BANK OF AMERICA CORP /DE/ removed 988,424 shares (-56.9%) from their portfolio in Q3 2025, for an estimated $39,813,718
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 770,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $31,015,600
- MILLENNIUM MANAGEMENT LLC removed 706,792 shares (-73.6%) from their portfolio in Q3 2025, for an estimated $28,469,581
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 704,007 shares (+82.2%) to their portfolio in Q3 2025, for an estimated $28,357,401
- VANGUARD GROUP INC added 670,770 shares (+11.4%) to their portfolio in Q3 2025, for an estimated $27,018,615
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CGON Analyst Ratings
Wall Street analysts have issued reports on $CGON in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 12/11/2025
- Truist Securities issued a "Buy" rating on 11/24/2025
- RBC Capital issued a "Outperform" rating on 11/17/2025
- Guggenheim issued a "Buy" rating on 10/08/2025
- JP Morgan issued a "Overweight" rating on 09/26/2025
- Morgan Stanley issued a "Overweight" rating on 09/17/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/15/2025
To track analyst ratings and price targets for $CGON, check out Quiver Quantitative's $CGON forecast page.
$CGON Price Targets
Multiple analysts have issued price targets for $CGON recently. We have seen 10 analysts offer price targets for $CGON in the last 6 months, with a median target of $66.0.
Here are some recent targets:
- Robert Driscoll from Wedbush set a target price of $70.0 on 12/11/2025
- Gregory Renza from Truist Securities set a target price of $62.0 on 11/24/2025
- Leonid Timashev from RBC Capital set a target price of $61.0 on 11/17/2025
- Brad Canino from Guggenheim set a target price of $90.0 on 10/08/2025
- Brian Cheng from JP Morgan set a target price of $47.0 on 09/26/2025
- Jeffrey Hung from Morgan Stanley set a target price of $79.0 on 09/17/2025
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $75.0 on 09/15/2025
Full Release
IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 8:15 am PT / 11:15 am ET. The conference is taking place at the Westin St. Francis San Francisco, California.
Interested parties may access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com . The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
[email protected]
Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
[email protected]
